USANA Health Sciences, Inc. (USNA) Position Reduced by Cubist Systematic Strategies LLC
Cubist Systematic Strategies LLC trimmed its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 59.9% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 11,302 shares of the company’s stock after selling 16,907 shares during the period. Cubist Systematic Strategies LLC’s holdings in USANA Health Sciences were worth $1,303,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of USNA. Robecosam AG bought a new stake in USANA Health Sciences during the first quarter worth about $126,000. SG Americas Securities LLC bought a new stake in USANA Health Sciences during the first quarter worth about $137,000. O Shaughnessy Asset Management LLC bought a new stake in USANA Health Sciences during the first quarter worth about $179,000. Susquehanna Fundamental Investments LLC bought a new stake in USANA Health Sciences during the first quarter worth about $206,000. Finally, Element Capital Management LLC bought a new stake in USANA Health Sciences during the first quarter worth about $211,000. Institutional investors and hedge funds own 56.40% of the company’s stock.
Separately, Pivotal Research reissued a “hold” rating and issued a $135.00 target price on shares of USANA Health Sciences in a research note on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $135.00.
USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, July 24th. The company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.25. USANA Health Sciences had a return on equity of 29.50% and a net margin of 7.16%. The company had revenue of $301.50 million during the quarter, compared to analyst estimates of $278.41 million. During the same quarter in the previous year, the company posted $0.98 EPS. USANA Health Sciences’s revenue for the quarter was up 17.3% on a year-over-year basis. analysts expect that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current year.
In other USANA Health Sciences news, Director Myron W. Wentz sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $131.20, for a total transaction of $19,680,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joshua Foukas sold 306 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $129.27, for a total value of $39,556.62. The disclosure for this sale can be found here. In the last three months, insiders bought 19,117 shares of company stock valued at $1,349,965 and sold 994,500 shares valued at $127,469,281. Insiders own 53.20% of the company’s stock.
USANA Health Sciences Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.